Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors

Ify R. Mordi; Chim C. Lang

doi:10.1016/j.hfc.2022.03.004

Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors

Ify R. Mordi, Chim C. Lang (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

67 Downloads (Pure)

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes in patients with heart failure with or without type 2 diabetes however the mechanisms contributing to these benefits remain poorly understood. While SGLT2 inhibitors do have glucose-lowering effects, it is unlikely that their cardiovascular benefits are solely due to improved glycemic control. This improved glycemia leads to consequent metabolic effects that could provide further explanation for their action. In this review we will discuss the glucose-lowering and metabolic effects of SGLT2 inhibitors and how these might lead to improved cardiovascular outcomes in patients with heart failure.

Original language	English
Pages (from-to)	529-538
Number of pages	10
Journal	Heart Failure Clinics
Volume	18
Issue number	4
Early online date	7 Oct 2022
DOIs	https://doi.org/10.1016/j.hfc.2022.03.004
Publication status	Published - Oct 2022

Keywords

SGLT2 inhibitors
glycaemia
cardio-metabolic
heart failure
Heart failure
Cardiometabolic
Glycemia

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hfc.2022.03.004Licence: Elsevier User Licence

Author Accepted ManuscriptAccepted author manuscript, 296 KBLicence: CC BY-NC-ND

Cite this

@article{c1d0b8ed0f114b93bf8f383c66ff8658,

title = "Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors",

abstract = "Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes in patients with heart failure with or without type 2 diabetes however the mechanisms contributing to these benefits remain poorly understood. While SGLT2 inhibitors do have glucose-lowering effects, it is unlikely that their cardiovascular benefits are solely due to improved glycemic control. This improved glycemia leads to consequent metabolic effects that could provide further explanation for their action. In this review we will discuss the glucose-lowering and metabolic effects of SGLT2 inhibitors and how these might lead to improved cardiovascular outcomes in patients with heart failure.",

keywords = "SGLT2 inhibitors, glycaemia, cardio-metabolic, heart failure, Heart failure, Cardiometabolic, Glycemia",

author = "Mordi, {Ify R.} and Lang, {Chim C.}",

note = "Funding Information: Dr I.R. Mordi has received speaker fees from Boehringer Ingelheim, United Kingdom and research funding from Astra Zeneca, United Kingdom. Dr C.C. Lang has received consultancy and speaker fees and research funding from AstraZeneca , Boehringer Ingelheim , and Novo Nordisk, Denmark and consultancy and speaker fees from MSD, United Kingdom. Copyright Information: {\textcopyright} 2022 Elsevier Inc. All rights reserved. ",

year = "2022",

month = oct,

doi = "10.1016/j.hfc.2022.03.004",

language = "English",

volume = "18",

pages = "529--538",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors

AU - Mordi, Ify R.

AU - Lang, Chim C.

N1 - Funding Information: Dr I.R. Mordi has received speaker fees from Boehringer Ingelheim, United Kingdom and research funding from Astra Zeneca, United Kingdom. Dr C.C. Lang has received consultancy and speaker fees and research funding from AstraZeneca , Boehringer Ingelheim , and Novo Nordisk, Denmark and consultancy and speaker fees from MSD, United Kingdom. Copyright Information: © 2022 Elsevier Inc. All rights reserved.

PY - 2022/10

Y1 - 2022/10

N2 - Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes in patients with heart failure with or without type 2 diabetes however the mechanisms contributing to these benefits remain poorly understood. While SGLT2 inhibitors do have glucose-lowering effects, it is unlikely that their cardiovascular benefits are solely due to improved glycemic control. This improved glycemia leads to consequent metabolic effects that could provide further explanation for their action. In this review we will discuss the glucose-lowering and metabolic effects of SGLT2 inhibitors and how these might lead to improved cardiovascular outcomes in patients with heart failure.

AB - Sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently demonstrated improved outcomes in patients with heart failure with or without type 2 diabetes however the mechanisms contributing to these benefits remain poorly understood. While SGLT2 inhibitors do have glucose-lowering effects, it is unlikely that their cardiovascular benefits are solely due to improved glycemic control. This improved glycemia leads to consequent metabolic effects that could provide further explanation for their action. In this review we will discuss the glucose-lowering and metabolic effects of SGLT2 inhibitors and how these might lead to improved cardiovascular outcomes in patients with heart failure.

KW - SGLT2 inhibitors

KW - glycaemia

KW - cardio-metabolic

KW - heart failure

KW - Heart failure

KW - Cardiometabolic

KW - Glycemia

UR - http://www.scopus.com/inward/record.url?scp=85139510457&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2022.03.004

DO - 10.1016/j.hfc.2022.03.004

M3 - Article

C2 - 36216483

SN - 1551-7136

VL - 18

SP - 529

EP - 538

JO - Heart Failure Clinics

JF - Heart Failure Clinics

IS - 4

ER -

Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

PRecision Medicine for Diabetis Individuals: a Joint Malaysia-UK Effort (PRIME) - (Joint with UMBI)

REnal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop DiurEtics in Diabetic Patients with Chronic Heart Failure (RECEDE-CHF)

Cite this

Glucose Lowering and Metabolic Effects of SGLT2 Inhibitors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

PRecision Medicine for Diabetis Individuals: a Joint Malaysia-UK Effort (PRIME) - (Joint with UMBI)

REnal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop DiurEtics in Diabetic Patients with Chronic Heart Failure (RECEDE-CHF)

Cite this